×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
IRWD – ironwood pharmaceuticals, inc. - class a (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
IRWD
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/23
07:32 am
irwd
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 [Yahoo! Finance]
Medium
Report
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026 [Yahoo! Finance]
4/23
07:05 am
irwd
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
Medium
Report
Ironwood Pharmaceuticals to Share Real-World HCP Perspectives on Burden of Total Parenteral Nutrition in Short Bowel Syndrome (SBS) at Digestive Disease Week® 2026
3/31
07:40 am
irwd
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why [Yahoo! Finance]
Medium
Report
Ironwood (IRWD) is One of the Most Attractive Small-Cap Drug Manufacturers, Here is Why [Yahoo! Finance]
3/4
04:05 pm
irwd
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
Low
Report
Ironwood Pharmaceuticals to Participate in The Citizens Life Sciences Conference
2/27
06:26 am
irwd
Ironwood Pharmaceuticals (IRWD) was downgraded by Zacks Research from "strong-buy" to "hold".
Medium
Report
Ironwood Pharmaceuticals (IRWD) was downgraded by Zacks Research from "strong-buy" to "hold".
2/26
09:42 pm
irwd
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance [Yahoo! Finance]
Medium
Report
A Look At Ironwood Pharmaceuticals (IRWD) Valuation After Q4 2025 Results And 2026 Revenue Guidance [Yahoo! Finance]
2/26
11:13 am
irwd
Ironwood Pharmaceuticals (IRWD) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..
Low
Report
Ironwood Pharmaceuticals (IRWD) had its "hold" rating reaffirmed by Jefferies Financial Group Inc..
2/26
09:55 am
irwd
Ironwood Pharmaceuticals (IRWD) had its price target raised by Citizens Jmp from $8.00 to $10.00. They now have a "market outperform" rating on the stock.
Low
Report
Ironwood Pharmaceuticals (IRWD) had its price target raised by Citizens Jmp from $8.00 to $10.00. They now have a "market outperform" rating on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
2/25/2026
07:05 am
irwd
ironwood pharmaceuticals, inc. - class a
MISS
Report
-5.6%
ironwood pharmaceuticals, inc. - class a
11/10/2025
07:05 am
irwd
ironwood pharmaceuticals, inc. - class a
BEAT
Report
17.7%
ironwood pharmaceuticals, inc. - class a
5/7/2025
07:05 am
irwd
ironwood pharmaceuticals, inc. - class a
MISS
Report
-13.0%
ironwood pharmaceuticals, inc. - class a
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/27
09:52 am
irwd
Form SCHEDULE 13G/A IRONWOOD PHARMACEUTICALS Filed by: VANGUARD GROUP INC
Low
Report
Form SCHEDULE 13G/A IRONWOOD PHARMACEUTICALS Filed by: VANGUARD GROUP INC
3/19
06:35 pm
irwd
Form SCHEDULE 13D/A IRONWOOD PHARMACEUTICALS Filed by: Sarissa Capital Management LP
Medium
Report
Form SCHEDULE 13D/A IRONWOOD PHARMACEUTICALS Filed by: Sarissa Capital Management LP
3/17
08:35 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 13 Filed by: DENNER ALEXANDER J
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 13 Filed by: DENNER ALEXANDER J
3/12
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: Martini Gregory S.
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: Martini Gregory S.
3/12
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: John Minardo
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: John Minardo
3/12
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: Silver Ronald
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: Silver Ronald
3/12
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: MCCOURT Thomas A
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: MCCOURT Thomas A
3/12
04:05 pm
irwd
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: Gaskins Tammi L
Low
Report
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 10 Filed by: Gaskins Tammi L
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
5/16
Form SC 13D IRONWOOD PHARMACEUTICALS Filed by: Sarissa Capital Management LP
11.5%
4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%
2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%
10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%
1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%
9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%
2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%
2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%
5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%
8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%
4/14 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. 7.5%
2/26 Ironwood Pharmaceuticals Announces Publication of Positive IW-3718 Phase IIb Data in Gastroenterology 7.5%
10/31 Q3/2019 9/30/2019 EPS 0.400 ZacksConsensus 0.100 ActVsEst 0.300 - Beat 6.5%
1/6 Ironwood and Allergan Announce Settlement Resolving LINZESS® (linaclotide) Patent Litigation 6.3%
9/11 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.8%
2/29 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 5.4%
2/13 Q4/2019 12/31/2019 EPS 0.300 ZacksConsensus 0.220 ActVsEst 0.080 - Beat 4.9%
5/31 Form 4 IRONWOOD PHARMACEUTICALS For: May 29 Filed by: Dreyfus Andrew 4.5%
8/13 Ironwood Pharmaceuticals and Alnylam Pharmaceuticals Enter U.S. GI Disease Education and Promotional Agreement for Alnylam’s Givosiran in Acute Hepatic Porphyria (AHP) 3.9%
TOP News Decliners
3/17
Form 4 IRONWOOD PHARMACEUTICALS For: Mar 13 Filed by: Dreyfus Andrew
-10.8%
7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%
2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%
6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%
6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%
8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%
3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%
10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%
8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%
4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%
7/31 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its "neutral" rating re-affirmed by analysts at Wedbush. They now have a $12.00 price target on the stock, up previously from $11.00. -9.1%
2/14 Form SC 13G/A IRONWOOD PHARMACEUTICALS Filed by: BROWN CAPITAL MANAGEMENT LLC -6.2%
6/18 Form 4 IRONWOOD PHARMACEUTICALS For: Jun 14 Filed by: Dreyfus Andrew -5.9%
6/13 Form 8-K IRONWOOD PHARMACEUTICALS For: Jun 11 -5.5%
8/6 Ironwood Pharmaceuticals Announced Proposed Offering of $330 Million of Convertible Senior Notes -5.2%
3/2 Form 4 IRONWOOD PHARMACEUTICALS For: Feb 27 Filed by: MacDonald Kelly -3.6%
10/17 Ironwood Pharmaceuticals to Host Third Quarter 2019 Investor Update Call -3.5%
8/13 Ironwood Pharmaceuticals Announces Full Exercise of Convertible Notes Over-Allotment -3.5%
4/15 Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) had its price target lowered by analysts at Morgan Stanley from $13.00 to $12.00. They now have an "equal weight" rating on the stock. -3.2%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: